First Trust Advisors LP Boosts Stock Holdings in Genmab A/S (NASDAQ:GMAB)

First Trust Advisors LP raised its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 18.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,644,288 shares of the company's stock after acquiring an additional 251,241 shares during the quarter. First Trust Advisors LP owned approximately 0.25% of Genmab A/S worth $34,316,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. grew its holdings in Genmab A/S by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company's stock worth $186,000 after acquiring an additional 827 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after purchasing an additional 939 shares during the period. Lindbrook Capital LLC grew its stake in shares of Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after purchasing an additional 950 shares during the last quarter. GAMMA Investing LLC increased its holdings in Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after purchasing an additional 1,051 shares during the period. Finally, Grandfield & Dodd LLC raised its position in Genmab A/S by 4.2% during the 4th quarter. Grandfield & Dodd LLC now owns 33,733 shares of the company's stock worth $704,000 after purchasing an additional 1,370 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Stock Performance

Shares of NASDAQ GMAB traded up $0.36 during trading on Wednesday, hitting $21.15. 1,354,443 shares of the company traded hands, compared to its average volume of 1,055,171. The business's fifty day moving average is $20.39 and its 200 day moving average is $21.00. The firm has a market capitalization of $13.56 billion, a price-to-earnings ratio of 12.16, a P/E/G ratio of 2.65 and a beta of 1.07. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $30.41.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, analysts predict that Genmab A/S will post 1.45 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Truist Financial reduced their price target on Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th. Leerink Partnrs raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. BNP Paribas upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 11th. Sanford C. Bernstein lowered shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research note on Tuesday, April 1st. Finally, William Blair upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $39.17.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.